Cantor Fitzgerald Reaffirms Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report)'s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports. They presently have a $18.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 173.97% from the company's current price.

Other equities analysts have also issued reports about the company. StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, September 10th. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, August 14th.

Abeona Therapeutics Stock Up 2.8 %

NASDAQ ABEO traded up $0.18 during trading on Tuesday, hitting $6.57. 500,323 shares of the company traded hands, compared to its average volume of 438,781. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The business has a fifty day simple moving average of $5.97 and a 200 day simple moving average of $5.18. The company has a current ratio of 7.48, a quick ratio of 7.48 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $269.13 million, a P/E ratio of -2.01 and a beta of 1.53.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.42). As a group, sell-side analysts predict that Abeona Therapeutics will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. abrdn plc boosted its holdings in Abeona Therapeutics by 158.8% during the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company's stock valued at $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $1,732,000. Renaissance Technologies LLC boosted its holdings in Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock valued at $2,134,000 after purchasing an additional 429,456 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after purchasing an additional 2,434 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in Abeona Therapeutics during the second quarter valued at approximately $7,420,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.